



12W


PATENT
ATTORNEY DOCKET NO. 50291/014002

Certificate of Mailing: Date of Deposit: April 26, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Jeremy Waterman

Printed name of person mailing correspondence


Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gervais et al.	Art Unit:	1649
Serial No.:	10/540,763	Examiner:	Kimberly A. Ballard
Filed:	November 18, 2005	Customer No.:	21559
Title:	Therapeutic Formulations for the Treatment of Beta-Amyloid Related Diseases		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: April 26, 2006

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50291/014002

Serial No.

10/540,763

Applicant

Gervais et al.

Filing Date

November 18, 2005

Group

1649

IDS Filed

April 26, 2006

(MODIFIED)

OIP E IAP 2

MAY 01 2006

PATENT & TRADEMARK OFFICE

(37 C.F.R. § 1.98(b))

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,331,440	12/18/01	Nordstedt et al.			
	2005/0031651	2/10/05	Gervais et al.			
	2005/0038000	2/17/05	Kong et al.			
	2005/0142191	6/30/05	Legore			
	2005/0143462	6/30/05	Kong et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 94/22437	10/13/94	WIPO			
	WO 96/28187	9/19/96	WIPO			
	WO 99/59571	11/25/99	WIPO			
	WO 00/52048	9/8/00	WIPO			
	WO 00/68263	11/16/00	WIPO			
	WO 01/85093	11/15/01	WIPO			
	WO 02/36614	5/10/02	WIPO			
	WO 02/96937	12/5/02	WIPO			
	WO 04/58258	07/15/04	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Conde, "Beta-Amyloid Peptide as a Target for Treatment of Alzheimer's Disease," Expert Opinion on Therapeutic Patents 12:503-512, 2002.
	Kisilevsky et al., "Arresting Amyloidosis <i>In Vivo</i> Using Small-Molecule Anionic Sulphonates or Sulphates: Implications for Alzheimer's Disease," Nat. Med. 1:143-148, 1995.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.